Skip to content

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

Home
Infectious Disease
Metabolic
Neurological
Nutrition
Public Health

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

Home
Infectious Disease
Metabolic
Neurological
Nutrition
Public Health

Roivant

FDA approves oral dermatomyositis drug

August 29, 2026 Evan Vega

FDA Approves Roivant’s Lisraya (brepocitinib) as First Oral Drug for Dermatomyositis

The FDA approved Roivant’s Lisraya (brepocitinib), the first oral dual TYK2/JAK1 inhibitor, to treat dermatomyositis in adults.

Copyright © 2026 DAILYZ HEALTH NEWS. Powered by ColorMag and WordPress.